Objective: To compare the tic suppression, electrocardiogram (ECG) changes, weight gain, and side effect profiles of pimozide versus risperidone in children and adolescents with tic disorders. Method: This was a randomized, double-blind, crossover (evaluable patient analysis) study. Nineteen children aged 7 to 17 years with Tourette's or chronic…

Objective: The Treatment of Early Onset Schizophrenia Spectrum Disorders Study is a publicly funded clinical trial designed to compare the therapeutic benefits, safety, and tolerability of risperidone, olanzapine, and molindone in youths with early-onset schizophrenia spectrum disorders. The rationale, design, and methods of the Treatment of Early…

Describes the use of risperidone in eight adult patients with moderate to profound mental retardation and markedly aberrant behaviors. Risperidone in these individuals was associated with significant reduction in aggression and self-injurious behavior. Side effects were primarily those of sedation and restlessness. (Author/CR)

Presents information on 24 and 34 months of successful treatment with Risperidone of a young woman and young man with autism and profound mental retardation. Treatment with Risperidone resulted in positive changes for aggressive, self-injurious, and anti-social behavior. After treatment, subjects were able to participate in social activities. (CR)

The use of risperidone for 10 individuals with mental retardation and mental health disturbances was evaluated using a case study approach to delineate the course of substitution of more traditional antipsychotic medications with risperidone. All participants showed improvement or resolution in side effects attributed to previous medication with…

Since their introduction, antipsychotic medications have been used widely to treat conditions other than psychiatric disorders, especially among individuals with mental retardation. Researchers have shown that the prevalence rates of psychotropic medication prescriptions among this population are extremely high. Given the limited empirical data to…

The efficacy of the atypical antipsychotic risperidone was evaluated in the treatment of aberrant behavior (e.g., aggression, self-injury) in 20 individuals with developmental disabilities. The study, a double-blind crossover design, identified 50 percent of participants as responders. Naturalistic observations of five participants showed that…

In this case series we report four cases of patients with Down syndrome with symptoms consistent with obsessive compulsive disorder. Each patient experienced substantial reduction in compulsive behaviors with pharmacotherapy of an SSRI alone or with the addition of risperidone to SSRI therapy. None of the patients experienced significant side…

The author of a paper on effects of risperidone on behavior in people with developmental disabilities rebuts a criticism by suggesting that a specific diagnosis of psychiatric disorder is unimportant, since risperidone was effective in reducing aberrant behavior regardless of psychiatric diagnosis and/or environmental contingencies. (Contains…

In this study, 11 males with autism and mental retardation were administered risperidone. Substantial clinical improvement was noted almost immediately; patients with aggression, self-injury, explosivity, and poor sleep hygiene were most improved. The modal dose for optimal response was 0.5 mg bid. Weight gain was a significant side effect.…

Consumer satisfaction and social validity were measured during a double-blind, placebo-controlled evaluation of risperidone in treating aberrant behaviors of persons with developmental disabilities. A survey showed all 17 caregivers felt participation was positive. Community members (n=52) also indicated that when on medication, the 5 participants…

This study reports marked reductions in self-injurious behavior and aggression of two adults with profound mental retardation treated with clozapine, who were non-responsive to all other behavioral and psychopharmacological interventions, including risperidone. The most effective dose was 200mg/day. Side effects were mild and the drug was…

In response to a paper on effects of risperidone on behavior in people with developmental disabilities, this paper raises the issue of how clinicians determine whether treatment should target the psychiatric disorder underlying the aberrant behavior (diagnosis-based treatment) or should target the aberrant behavior directly (behavior-based…

The atypical antipsychotic medication risperidone was evaluated using a double-blind, placebo-controlled design to treat destructive behavior in two males (ages 6 and 24) with autism. Destructive behavior during the demand condition was significantly reduced during the medication phases, whereas it continued to occur to obtain tangible items and…

Background: Psychopharmacological intervention in the management of behaviour problems in adults with intellectual disabilities (ID) has become a common treatment strategy. This has become a cause for concern, given that the evidence for its effectiveness is uncertain and most drugs are not licensed for this use. Methods: A comprehensive…